drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody
drug_description
An intravenous anti-GD2 IgG1 monoclonal antibody that binds GD2 on neuroblastoma cells and induces antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
naxitamab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Naxitamab is an IgG1 monoclonal antibody that binds the GD2 antigen on neuroblastoma cells and mediates tumor cell killing primarily through antibody-dependent cellular cytotoxicity (via NK cells and macrophages) and complement-dependent cytotoxicity, leading to immune-mediated lysis of GD2-expressing cells.
drug_name
Naxitamab (Danyelza)
nct_id_drug_ref
NCT06540963